전립선비대증과 성기능장애 = Benign Prostatic Hyperplasia and Sexual Dysfunction

다국어 초록 (Multilingual Abstract)

Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) and declines in male sexual function are common manifestations of aging, and have been associated with each other in a number of clinical and epidemiological studies. Erectile and ejaculatory function declines with age-adjusted LUTS severity as well as age itself. Although urinary symptoms and quality of life may improve with BPH therapy, the resulting effects on sexual function vary by medical or surgical treatment. Alpha-blockers improve sexual function and phosphodiesterase type 5 (PDE5) inhibitors decline LUTS scores. PDE5 inhibitors approved for daily use may represent an important new therapeutic opportunity for men with BPH-LUTS and erectile dysfunction. Larger studies on the combination of an alpha-blocker for BPH and a PDE5 inhibitor are necessary to develop an integrated treatment approach for BPH-LUTS patients with erectile dysfunction.

참고문헌 (Reference)

1 차재성, "하부요로증상과 발기부전의 연관성" 대한비뇨기과학회 46 (46): 1023-1027, 2005

2 용득중, "하부요로 증상에 따른 발기능과 성교 횟수의 비교" 대한비뇨기과학회 48 (48): 458-462, 2007

3 정우식, "전립선비대증과 발기부전: 그 연관성의 실체는?" 대한남성과학회 23 (23): 111-115, 2005

4 박종관, "전립선 비대증 환자에서 알파 1 교감신경수용체 차단제Tamsulosin이 성기능에 미치는 영향" 대한남성과학회 22 (22): 146-150, 2004

5 제성욱, "알파차단제 투여 후 하부요로증상 및 성기능의 개선 효과" 대한비뇨기과학회 50 (50): 369-374, 2009

6 손환철, "서울지역 40세 이상 남성의 성기능장애의 유병률: 설문지에 의한 역학조사" 대한비뇨기과학회 43 (43): 52-61, 2002

7 이정구, "남성하부요로증상의 병인" 대한비뇨기과학회 46 (46): 887-896, 2005

8 Gacci M, "Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study" 178 : 2040-2043, 2007

9 Dmochowski R, "Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial" 183 : 1092-1097, 2010

10 Cho JJ, "The nongenomic protective effects of estrogen on the male cardiovascular system: clinical and therapeutic implications in aging men" 9 : RA63-68, 2003

11 Schiff JD, "The link between LUTS and ED: clinical and basic science evidence" 25 : 470-478, 2004

12 Wein AJ, "The impact of lower urinary tract symptoms on male sexual health: EpiLUTS" 103 (103): 33-41, 2009

13 Ponholzer A, "The association between vascular risk factors and lower urinary tract symptoms in both sexes" 50 : 581-586, 2006

14 문두건, "The Efficacy and Safety of Tamsulosin 0.2mg/day on Sexual Function in BPH: A Multicenter Open-label, Non-comparative, 3 Months Observational, Phase IV Prospective Study" 대한남성과학회 27 (27): 123-129, 2009

15 Kayes O, "Tamsulosin and intraoperative ‘floppy iris' syndrome--keeping an eye on the problem" 106 : 2-3, 2010

16 McVary KT, "Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia" 177 : 1401-1407, 2007

17 Roehrborn CG, "Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study" 180 : 1228-1234, 2008

18 McVary KT, "Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial" 177 : 1071-1077, 2007

19 Tuncel A, "Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction" 28 : 17-22, 2010

20 Oh SJ, "Sexual status following prostatectomy" 10 : 135-142, 1992

21 Nehra A, "Selecting therapy for maintaining sexual function in patients with benign prostatic hyperplasia" 96 : 237-243, 2005

22 Chung BH, "Safety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/ LUTS" 21 : 122-128, 2009

23 Martín-Morales A, "Prevalence of ejaculatory dysfunction secondary to alpha-blocker therapy in patients with benign prostatic hyperplasia" 32 : 705-712, 2008

24 Skolarus TA, "Measurement of benign prostatic hyperplasia treatment effects on male sexual function" 21 : 267-274, 2009

25 Paick JS, "Male sexual dysfunction associated with the treatment for benign prostatic hyperplasia" 16 : 121-128, 1998

26 Rosen RC, "Lower urinary tract symptoms and sexual health: the role of gender, lifestyle and medical comorbities" 103 (103): 42-47, 2009

27 Chung WS, "Lower urinary tract symptoms and sexual dysfunction in community- dwelling men" 79 : 745-749, 2004

28 Rosen R, "Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7)" 44 : 637-649, 2003

29 Braun MH, "Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical “Aging Male” symptoms? Results of the “Cologne Male Survey”" 44 : 588-594, 2003

30 Hansen BL, "Lower urinary tract symptoms (LUTS) and sexual function in both sexes" 46 : 229-234, 2004

31 Walden PD, "Localization and expression of the alpha 1A, alpha 1B and apha 1D- adrenoceptors in hyperplastic and non-hyperplastic human prostate" 161 : 635-640, 1999

32 Jannini EA, "Is sex just fun? How sexual activity improves health" 2009 (2009): 2640-2648,

33 Kloner RA, "Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men" 172 : 1935-1940, 2004

34 Feldman HA, "Impotence and its medical and psychological correlates: result of the Massachusetts Male Aging Study" 151 : 54-61, 1994

35 Korfage IJ, "Erectile dysfunction and mental health in a general population of older men" 6 : 505-512, 2009

36 Cai H, "Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress" 87 : 840-844, 2000

37 Broderick GA, "Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction" 75 : 1452-1458, 2010

38 Uckert S, "Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue" 71 : 526-530, 2008

39 Porst H, "Effects of once- daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia" 56 : 727-735, 2009

40 Park KH, "Effects of androgens on the expression of nitric oxide synthase mRNAs in rat corpus cavernosum" 83 : 327-333, 1999

41 Ng CF, "Effect of vardenafil on blood pressure profile of patients with erectile dysfunction concomitantly treated with doxazosin gastrointestinal therapeutic system for benign prostatic hyperplasia" 180 : 1042-1046, 2008

42 Bloch W, "Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide" 33 : 1-8, 1997

43 Bechara A, "Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH: pilot study" 5 : 2170-2178, 2008

44 Carson CC, "Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?" 97 (97): 39-43, 2006

45 Kaplan SA, "Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction" 51 : 1717-1723, 2007

46 Uckert S, "Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate" 166 : 2484-2490, 2001

47 Medina JJ, "Benign prostatic hyperplasia (the aging prostate)" 83 : 1213-1229, 1999

48 McVary KT, "Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia" 174 : 1327-1333, 2005

49 Ponholzer A, "Association between lower urinary tract symptoms and erectile dysfunction" 64 : 772-776, 2004

50 Barton M, "Anatomic heterogenecity of vascular aging: role of nitric oxide and endothelin" 30 : 817-824, 1997

51 Kim MK, "An open, non-comparative, multicentre study on the impact of alfuzosin on sexual function using the Male Sexual Health Questionnaire in patients with benign prostate hyperplasia" 64 : 345-350, 2010

52 Li MK, "An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function" 101 : 197-202, 2008

53 Yassin A, "Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice" 38 : 1-12, 2006

54 Tarcan T, "Age-related erectile and voiding dysfunction: the role of arterial insufficiency" 82 : 26-33, 1998

55 McVary KT, "A review of combination therapy in patients with benign prostatic hyperplasia" 29 : 387-398, 2007

56 Stief CG, "A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia" 53 : 1236-1244, 2008

57 Mondul AM, "A prospective study of lower urinary tract symptoms and erectile dysfunction" 179 : 2321-2326, 2008

58 Tamimi NA, "A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia" 106 : 674-680, 2010